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Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2). Early detection of COVID-19 and imme-
diate isolation of infected patients from the naive population are important to prevent fur-
ther pandemic spread of the infection. Real-time reverse transcription (RT)-PCR to detect 
SARS-CoV-2 RNA is currently the most reliable diagnostic method for confirming COVID-19 
worldwide. Guidelines for clinical laboratories on the COVID-19 diagnosis have been re-
cently published by Korean Society for Laboratory Medicine and the Korea Centers for 
Disease Control and Prevention. However, these formal guidelines do not address com-
mon practical laboratory issues related to COVID-19 real-time RT-PCR testing and their 
solutions. Therefore, this guideline is intended as a practical and technical supplement to 
the “Guidelines for Laboratory Diagnosis of COVID-19 in Korea”.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a respiratory disease 
caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) [1], which was first identified in Wuhan, China, in De-
cember 2019, and has rapidly spread globally, resulting in the 
ongoing pandemic [2]. Recently, Korean Society for Laboratory 
Medicine (KSLM) and the Korea Centers for Disease Control 
and Prevention (KCDC) published guidelines for diagnosing CO-
VID-19 in clinical laboratories in Korea [3]. These guidelines 
provide appropriate solutions to COVID-19 diagnosis. However, 
many practical and technical issues frequently arise in clinical 
laboratories conducting COVID-19 testing, including those in-
volving nucleic acid extraction, nucleic acid amplification re-
agents, and interpretation of test results. The COVID-19 Diagno-
sis Test Management Committee was established by the KCDC 
on Feb 28, 2020, to provide appropriate solutions to such mat-
ters in the field through careful review and counseling by spe-
cialized experts in the public and private sectors. On behalf of 
the COVID-19 Diagnosis Test Management Committee, we pres-
ent supplementary information to the “Guidelines for Laboratory 
Diagnosis of COVID-19 in Korea” to provide solutions for practi-
cal issues faced when conducting COVID-19 diagnostic testing 
using real-time reverse transcription (RT)-PCR [3]. These prac-
tical guidelines are mostly based on expert opinions regarding 
samples, nucleic acid extraction, nucleic acid amplification re-
agents, and interpretation of test results and have been formed 
with the experience from more than 700,000 COVID-19 tests 
using five emergency use authorization (EUA) assays in Korea.
This guideline was exempted from review by the Asan Medi-
cal Center’s Institutional Review Board, Seoul, Korea, owing to its 
minimal risk and exemption category fulfillment, including analy-
sis of previously collected information [cycle threshold (Ct) val-
ues of samples], without requiring clinical data from other pa-
tients [AMC IRB 2020-0548].
WHAT SAMPLES SHOULD BE TESTED?
In principle, we recommend simultaneous testing of upper and 
lower respiratory tract samples [3, 4]; however, testing of an upper 
respiratory tract sample alone may be unavoidable when sputum 
cannot be obtained [3]. In case of upper respiratory tract sam-
ples, several guidelines recommend using a universal transport 
medium (UTM) for nasopharyngeal (NP) and oropharyngeal (OP) 
swabs to increase test sensitivity [3-5]. Since several flocked swab 
products have one swab and one UTM tube, two sets of swabs 
should be used to place both NP swab and OP swab in the same 
UTM. Considering the current short supply of flocked swabs, us-
ing only the NP swab can be considered. NP swabs resulted in a 
higher positive rate than OP swabs [6]. Further, our data showed 
lower Ct values in NP swabs than in OP swabs (Table 1).
WHAT TYPE OF FLOCKED SWAB PRODUCTS 
ARE AVAILABLE IN KOREA?
FLOQSwab (Copán, Brescia, Italy) in eNAT (Copán) and UTM 
(Copán) is a flocked swab available in Korea that is easy to use 
because it has a red line at the molded break point (Fig. 1A). 
Since eNAT contains guanidine thiocyanate (a type of chaotropic 
salt) that prevents the degradation of nucleic acids in the me-
dium, it is a good option when testing microbial nucleic acids 
only; the same applies to the COVID-19 real-time RT-PCR test. 
HydraFlocked (Diagnostic Hybrids, Athens, OH, USA) and NFS-
Swab Applicator (Noble Bio, Hwaseong, Korea) do not include a 
red line at the molded break point (Fig. 1A). In addition, it is dif-
ficult to break the shaft of an NFS-Swab Applicator. The product 
Table 1. Cycle threshold values of nasopharyngeal swabs and oropharyngeal swabs from five COVID-19 patients, tested using the Allplex 
2019-nCoV kit (Seegene, Seoul, Korea)
Patient
Nasopharyngeal swab Oropharyngeal swab
E gene RdRp gene N gene E gene RdRp gene N gene
1 22.61 24.88 25.18 24.59 29.66 31.65
2 21.88 23.42 25.10 ND 37.61 39.46
3 18.64 20.70 21.15 18.74 20.86 22.58
4 17.75 18.95 21.04 27.59 28.63 31.06
5 19.28 20.34 22.70 24.06 25.47 28.39
Median (range) 19.28 (17.75–22.61) 20.34 (18.95–24.88) 22.70 (21.04–25.18) 24.33 (18.74–27.59) 28.63 (20.86–37.61) 31.06 (22.58–39.46)
Abbreviation: ND, not detected. 
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manual recommends inserting the shaft groove between the lid 
and the rim of the tube to facilitate breaking (Fig. 1B). When us-
ing REST UTM (Noble Bio), it is important to vortex the sample 
thoroughly to remove cells from the swab, since the swab does 
not contain any beads.
SPUTUM PRE-TREATMENT IS DIFFICULT:  
IS THERE A SIMPLE METHOD?
The best-known method for sputum homogenization for Middle 
East respiratory syndrome virus tests is proteinase K and DNase 
I treatment [7]. The optimal temperature for proteinase K activ-
ity ranges from 50°C to 65°C. However, heat inactivation of sam-
ples through treatment at 56°C for 30 minutes was shown to 
adversely affect the efficiency of RT-PCR for SARS-CoV-2 detec-
tion [8]; therefore, proteinase K treatment at 50–65°C is not 
recommended for COVID-19 real-time RT-PCR. Use of N-acetyl-
L-cysteine dissolved in a sodium citrate solution is also a feasi-
ble option for sputum homogenization although the prepared 
solution is valid for only 24 hours. Caution is required to avoid 
excessive dilution of the sample due to the addition of a large 
amount of phosphate-buffered saline (PBS) during homogeni-
zation. Good results can be expected by adding 500 μL of spu-
tum to a 2-mL microtube (using a swab), mixing with the same 
amount of PBS or UTM with glass beads, sufficiently vortexing 
and centrifuging, and then using only the supernatant for ex-
traction. A sputum sample mixed and homogenized with the 
same amount of Liquillizer (MetaSystems, Altlussheim, Germany) 
can also be used for molecular diagnosis and sputum culture. 
Although access to the Liquillizer reagent is hindered owing to 
its limited distribution in Korea, it has excellent mucolytic and 
homogenizing performance.
WHAT EVALUATIONS ARE NEEDED FOR 
CHOOSING NUCLEIC ACID EXTRACTION 
REAGENTS AND INSTRUMENTS?
Before selecting or using a reagent for nucleic acid extraction in 
a laboratory, it is important to determine its performance in ex-
tracting nucleic acids from respiratory tract samples. We recom-
mend comparing the performance of the proposed extraction 
reagent with that of the reagent from the QIAamp Viral RNA 
Mini Kit (Qiagen, Hilden, Germany). Nucleic acids should be 
extracted from more than 30 respiratory virus samples, includ-
ing 10 or more respiratory virus-positive samples, using the pro-
posed extraction reagent simultaneously with the QIAamp Viral 
RNA Mini Kit extraction reagent. Respiratory virus multiplex 
PCR should then be performed, and the positive rate of extrac-
tion and Ct values of the target viral gene and internal control 
(IC) for the proposed reagent should be compared with those 
for the QIAamp Viral RNA Mini Kit extraction reagent. Although 
there are no definitive criteria for assessment, a reagent is gen-
erally considered comparable in performance to that of the 
QIAamp Viral RNA Mini Kit extraction reagent, if the Ct value 
difference is ≤1.66 of 0.5 log10 copies/mL equivalents [9,10].
Reagent supply stability should be considered when using 
imported reagents, such as MagNA Pure 96 (Roche Molecular 
Systems, Pleasanton, CA, USA), NucliSens easyMAG (bioMéri-
eux, Marcy l’Etoile, France), and Qiagen EZ1 Advanced XL (Qia-
gen).
WHICH REAL-TIME RT-PCR ASSAYS HAVE 
BEEN APPROVED IN KOREA FOR EMERGENCY 
USE TO DIAGNOSE COVID-19?
As of May 18, 2020, six real-time RT-PCR assays have been ap-
proved in Korea under EUA (Table 2). The PowerChek 2019-
nCoV kit (Kogenebiotech, Seoul, Korea) uses two PCR tubes per 
sample, while the other assays require only one PCR tube per 
sample. The product manual of the DiaPlexQ 2019-nCoV kit 
(SolGent, Daejeon, Korea) states that a sample can indicate CO-
VID-19 infection if the result for one of the two genes is positive. 
Fig. 1. Swab products available in Korea and how to use them. (A) 
Commercial flocked swabs and universal transport media (UTM). 
eNAT and FLOQSwab (Copán, Brescia, Italy), UTM and FLOQSwab 
(Copán), UTM (Copán) and HydraFlocked (Diagnostic Hybrids, 
Athens, OH, USA), and REST UTM and NFS-Swab Applicator (No-
ble Bio, Hwaseong, Korea) (left to right). (B) Breaking swab shaft 
between lid and upper rim of UTM.
Abbreviation: UTM, universal transport medium.
A B
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This is in contrast with the KSLM guidelines, which specifies 
that confirmation of COVID-19 requires positive results for all 
genes [3]. Since the Real-Q 2019-nCoV kit (BioSewoom, Seoul, 
Korea) and BioCore 2019-nCoV Real Time PCR kit (BioCore, 
Seoul, Korea) use the human nuclear RNase P and human 
β-globin genes as the IC, the Ct value of the IC is increased pro-
portionally to the dilution factor, if the sample or RNA is diluted 
for retesting. As KSLM and the KCDC have only evaluated the 
CFX96 Real-Time Detection System (Bio-Rad, Hercules, CA, 
USA) and the Applied Biosystems 7500 FAST and 7500 Real-
Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA) 
for six EUA assays [11], performance of the device intended for 
use should be compared.
WHAT EVALUATION METHOD IS APPROPRIATE 
WHEN CHANGING OR ADDING EUA ASSAYS 
FOR CONFIRMATION OR FOLLOW-UP TESTS?
To change or add EUA assays, parallel tests using at least 10 
positive and 10 negative samples should be performed, and the 
results should be reviewed by the person in charge of the labo-
ratory. The fourth external quality assessment by the Korean As-
sociation of External Quality Assessment Service used an inacti-
vated culture of SARS-CoV-2 [12]. This sample can be used for 
parallel tests.
WHY IS RETESTING NECESSARY WHEN THE 
IC IS NOT AMPLIFIED USING ALLPLEX 2019-
nCOV OR STANDARD M nCOV REAL-TIME 
DETECTION, AND HOW CAN THIS RETESTING 
BE CONDUCTED?
Both Allplex 2019-nCoV (Seegene, Seoul, Korea) and Standard 
M nCoV Real-Time Detection kits (SD Biosensors, Suwon, Ko-
rea) have the advantage of facilitating the observation of the en-
tire process of COVID-19 molecular testing to check nucleic acid 
extraction, the impact of the PCR inhibitor, and nucleic acid am-
plification since the IC is directly added to the sample before 
nucleic acid extraction. It is not possible to check the nucleic 
acid extraction with other assays in that the IC is added directly 
Table 2. The characteristics of six EUA real-time RT-PCR assays for COVID-19 diagnosis 











E, RdRp 2   5 Recombinant 
plasmid DNA
PCR mixture Applied Biosystems 7500 FAST and 
7500 Real-Time PCR System 
(Thermo Fisher Scientific, Waltham, 
MA, USA), CFX96 Real-Time 
Detection System (Bio-Rad, 
Hercules, CA, USA)*
E Ct ≤35 and 
RdRp Ct ≤35
Allplex 2019-nCoV  
(Seegene, Seoul, Korea)
E, RdRp, N 1   8 Bacteriophage Sample CFX96 Real-Time Detection System E Ct ≤40,  
RdRp Ct ≤40, 
and N Ct ≤40
Standard M nCoV Real-Time 




1 10 Lentivirus PCR mixture 
(0.5 μL) or 
sample (5 μL)
Applied Biosystems 7500 FAST and 
7500 Real-Time PCR System,  
CFX96 Real-Time Detection System†
E Ct ≤36 and 
ORF1ab  
Ct ≤36
DiaPlexQ 2019-nCoV (Solgent, 
Daejeon, Korea)




PCR mixture Applied Biosystems 7500 FAST and 
7500 Real-Time PCR System,  
CFX96 Real-Time Detection System




E, RdRp 1   5 Human RNase P 
gene (intrinsic)
- Applied Biosystems 7500 FAST and 
7500 Real-Time PCR System,  
CFX96 Real-Time Detection System
E Ct <38 and 
RdRp Ct <38
BioCore 2019-nCoV Real Time 
PCR (BioCore, Seoul, Korea)
N, RdRp 1   5  Human β-globin 
gene (intrinsic)
- Applied Biosystems 7500 FAST and 
7500 Real-Time PCR System, CFX96 
Real-Time Detection System‡
N Ct ≤40 and 
RdRp Ct ≤40
This table was modified from Table 1 by Hong, et al. [3] with permission from Annals of Laboratory Medicine.
Manufacturer claimed *Gentier 96E Real-Time PCR System (Tianlong Science & Technology, Xi’an, China), †LightCycler 480 Instrument (Roche, Pleasanton, 
CA, USA), and ‡SLAN 96P Real Time PCR System (Sansure Biotech, Hunan, China) can be used.
Abbreviations: IC, internal control; Ct, cycle threshold.
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into the PCR mixture (Table 2). 
When using a nucleic acid extraction reagent that requires 
the sample to be suspended in lysis buffer, the sample should 
be added to the lysis buffer prior to the IC. Although sodium do-
decyl sulfate, a detergent in the lysis buffer, has almost no im-
pact on nucleic acids (DNA and RNA), since it has a negative 
charge, we recommend following the above procedure when 
adding a small amount of the IC in a large volume of lysis buffer 
to prevent possible damage of the bacteriophage or lentivirus 
RNA. Further proper addition of the IC to the sample should 
also be confirmed, since 5–10 μL is a minor amount. If the IC is 
placed at the top (rim) of a reaction tube (or reaction well), am-
plification failure may occur due to inadequate mixing with the 
sample. The IC of the “Positive Control” of Allplex 2019-nCoV 
kit is plasmid DNA. The deviation of the Ct value from the IC of 
the “Positive Control” can be large when using immediately 
thawed reagent. Therefore, it is necessary to extract and test the 
sample again if there is no amplification of the IC. If there is still 
no amplification of the IC after re-extraction and retesting, we 
recommend performing a retest using a separate sample. When 
obtaining another sample is not feasible, the possibility of the 
presence of PCR inhibitors in the extracted nucleic acid solution 
should be ruled out using the current testing material. We rec-
ommend diluting the extracted nucleic acids by a factor of 10 in 
a retest in this case.
CAN SENSITIVITY BE INCREASED BY ADDING 
MORE “INPUT” RNA FOR RETESTING?
It is possible to improve the test sensitivity by increasing the 
amount of the “input” RNA using the extracted RNA instead of 
“DNase-, RNase-free distilled water” to reach the final PCR vol-
ume required. However, we do not recommend this option since 
this also typically results in the addition of more PCR inhibitors. 
As mentioned above, a 10-fold dilution of the RNA can be con-
sidered in a retest, if the IC is not amplified.
WHAT IS THE CONCLUSION WHEN UPPER 
AND LOWER RESPIRATORY TRACT SAMPLES 
YIELD DIFFERENT RESULTS?
In the case of different results between upper and lower respira-
tory tract samples, the first step would be to check for any cleri-
cal error (e.g., misidentification of patient name or hospital iden-
tification number, labeling error, or switched samples). In addi-
tion, the adequacy of the two samples from the patient should 
be considered; it is reasonable to presume that the sputum may 
not be “appropriate.” Moreover, the level of pre-treatment (mu-
colytic and homogenization) of the sputum should be consid-
ered. Infection can be confirmed with a positive result from ei-
ther sample when the criteria described below are met.
WHAT IS THE INTERPRETATION WHEN THE  
E GENE IS AMPLIFIED BUT THE RDRP GENE 
IS NOT: SARS CORONAVIRUS (SARS-COV)-
POSITIVE OR SARS-LIKE BETA-CORONAVIRUS?
The two SARS-like beta coronaviruses (sarbecoviruses) that in-
fect humans are the SARS-CoV-2 strain that is currently active 
and SARS-CoV that emerged in 2003 [13]. There is no evidence 
that SARS-CoV has reappeared. The E gene is not amplified 
from beta coronaviruses (e.g., OC43 and HKU1) other than sar-
becoviruses [13]. Therefore, if the test shows an E-positive and 
RdRp-negative result, the position of the E gene reaction well 
(PCR tube) should be checked for its proximity to the positive 
control well, which could suggest the possibility of cross-con-
tamination; in this case, extraction and retesting of the sample 
is necessary. This situation is applicable only to newly diagnosed 
patients (first testing of the first sample). Only one of the target 
genes (E gene, RdRp gene, and N gene) may show positivity 
during the follow-up test of a confirmed case.
When using the Allplex 2019-nCoV kit, if the Seegene Viewer 
shows positive Ct values in the 20s for the E gene only, the am-
plification curve should be evaluated, separately selecting the 
6-carboxyfluorescein (6-FAM) channel. A nonspecific reaction 
curve will appear, similar to the graph shown in Fig. 2.
WHAT ARE THE CAUSE, INTERPRETATION, 
AND SOLUTION FOR AMPLIFICATION AT THE 
END OF PCR IN THE NEGATIVE CONTROL 
WITH A NORMAL, EXPONENTIALLY 
INCREASING AMPLIFICATION CURVE?
One of the possible causes for negative control amplification is 
template contamination from the environment or amplicon [14]. 
To check the source, a wipe test of the biosafety cabinet (BSC), 
micropipette, extraction device, PCR workstation, and PCR de-
vice that handles the samples should be performed [15]. Or al-
ternatively, a flocked swab for NP swab collection could be used 
for the surface of the device equivalent to a sheet of A4 paper. 
The surface should be scraped to collect the sample and then 
be tested in the same manner as that used for testing a patient’s 
Sung H, et al.
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sample. Another possible cause for negative control amplifica-
tion is random nonspecific amplification or probe instability. In 
that case, a similar nonspecific amplification would occur in the 
patient’s sample reaction well, and retesting would often show a 
clean negative result.
SHOULD THE MANUFACTURER’S 
INSTRUCTIONS FOR THE CT VALUE BE 
FOLLOWED TO DETERMINE A POSITIVE OR 
NEGATIVE RESULT OBTAINED USING SARS-
COV-2 REAL-TIME RT-PCR?
The currently available assays have been approved for emer-
gency use; therefore, the results obtained using them require 
careful interpretation. Multiple genes from the same sample 
should be detected (i.e., simultaneous detection of the E gene 
and RdRp gene) and analyzed with another sample collected 
from the same patient (i.e., the sputum and NP swab together). 
Consider re-extraction and retesting, particularly using another 
sample for hospitalized patients.
With the Allplex 2019-nCoV kit, the Ct value of the E gene in a 
positive sample is 1.2–1.5 cycles lower on average than that of 
the RdRp gene, and the Ct value of the RdRp gene is approxi-
mately 1.5 cycles lower on average than that of the N gene. For 
samples with a high viral load, it is helpful to confirm, if the Ct 
values of the individual genes are observed in the expected or-
der. With the PowerChek 2019-nCoV kit, the E gene Ct value of 
the positive sample is lower than that of the RdRp gene, and the 
difference between the Ct values of these genes is approximately 
2.5. However, with the Standard M nCoV Real-Time detection 
Fig. 2. Nonspecific E gene amplification using Allplex 2019-nCoV assay. (A) Raw data obtained using Seegene Viewer (Seegene, Seoul, 
Korea). (B) Raw data obtained using CFX96 Real-Time Detection System. Circles show non-exponential noise curves. 
A
B
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kit, the RdRp gene Ct value is lower by approximately 1.5 cycles 
than that of the E gene Ct value (data not shown). SARS-CoV-2 
infection can be confirmed without retesting when the Ct values 
of the E and RdRp genes are 33.5 cycles or lower. However, check-
ing the position of the reaction well (PCR tube) near the positive 
control is also necessary to eliminate the possibility of cross-con-
tamination and verify that the amplification sequence of the E, 
RdRp, and N genes follows that order (in the case of the Allplex 
2019-nCoV kit).
The theoretical Ct value to amplify one copy of a target gene 
using a 20-μL PCR is 37 [16]. However, the Ct value correspond-
ing to one-copy amplification may differ in actual samples due 
to various factors, such as the presence of PCR inhibitors in the 
sample, activity of the one-step RT-PCR enzyme, and the fluo-
rescence sensitivity of the device. In the case of the PowerChek 
2019-nCoV kit, the RdRp gene may show an amplification curve 
at the end of the amplification stage (upward drift). Such an up-
ward drift of the RdRp gene without E gene amplification indi-
cates a likely negative result. In that case, re-extraction and re-
testing should be considered. If obtaining another sample is not 
possible, a common situation for many referral laboratories, we 
recommend a retest when the Ct value of either the E or the RdRp 
gene is higher than 33.5 and below 40 (the gray zone suggested 
by the Committee).
A negative result can be confirmed if the retest result is nega-
tive, and a positive result can be confirmed if the retest result 
shows that the Ct values of both the E and RdRp genes are 33.5 
or lower. A result of “indeterminate” should be reported followed 
by a retest with another sample, if the retest result of the sample 
is “indeterminate.”
WHAT ARE THE CRITERIA FOR A FOLLOW-UP 
TEST TO DETERMINE WHETHER TO RELEASE 
A CONFIRMED PATIENT FROM QUARANTINE?
Table 3 shows the daily test results of a patient who was con-
firmed to be infected with SARS-CoV-2 using the Allplex 2019-
nCoV kit, as an example for follow-up to make a decision for re-
lease from quarantine (note that this does not represent a typi-
cal case). 
When retesting a follow-up sample, some genes are often de-
tected and some are not, and the types of detected genes often 
change (Table 3). For example, a retest of a sample that was 
positive for both the E and N genes in the first test may show 
that the sample is positive for the RdRp and N genes in the fol-
low-up. Based on the experience from hospitals with many con-
Table 3. Representative serial results of cycle threshold values from SARS-CoV-2 real-time RT-PCR assay
Hospital day
Sputum Nasopharyngeal swab
E gene RdRp gene N gene Interpretation E gene RdRp gene N gene Interpretation
  9 22.61 24.68 26.24 Positive 32.78 34.50 34.06 Positive
10 ND 38.70 37.35 Indeterminate 34.09 36.79 35.81 Positive
11 35.42 ND 37.13 Indeterminate ND ND ND Negative
12 ND ND ND Negative ND ND ND Negative
13 ND 39.14 ND Indeterminate ND ND ND Negative
14 ND ND ND Negative ND ND ND Negative
15 ND ND 38.42 Indeterminate ND ND 38.56 Indeterminate
16 33.60 37.34 38.94 Positive ND 37.64 36.51 Indeterminate
17 ND 35.65 ND Indeterminate ND ND 38.56 Indeterminate
18 ND ND ND Negative 34.63 32.71 35.39 Positive
19 ND ND ND Negative ND ND 39.16 Indeterminate
20 32.48 ND 34.11 Indeterminate ND ND ND Negative
21 ND ND ND Negative ND ND ND Negative
22 ND ND ND Negative ND 37.60 ND Indeterminate
23 NT NT NT - ND ND ND Negative
24* NT NT NT - ND ND ND Negative
*Patient was discharged.
Abbreviations: ND, not detected; NT, not tested; RT-PCR, reverse-transcription PCR.  
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firmed patients, the N gene appears to remain detectable longer 
than other genes in many cases. Therefore, it is important to in-
terpret the results carefully when a sample from a confirmed 
patient is being tested for deciding on quarantine release. Avoid-
ing simple application of the manufacturers’ suggested interpre-
tation criteria is strongly advised. We recommend reporting the 
result as “positive” regardless of the Ct value if all target genes 
of the kit are amplified in the follow-up sample of a confirmed 
patient. An “Indeterminate (inconclusive)” result should be re-
ported, if one or more, but not all genes included in the kit show 
an amplification curve after the cut-off when using a follow-up 
sample. If the amplification curve shows an exponential func-
tion, an “indeterminate” result should be reported, along with 
an explanation to clinicians that this does not mean “negative.” 
This should be explicitly stated in the report in the case of a con-
firmed patient’s sample being tested at a referral laboratory.
The KCDC’s criteria for the quarantine release of patients with 
COVID-19 include clinical improvement with negative results 
from at least two consecutive respiratory samples collected ≥24 
hours apart [17]. As for the United States Centers for Disease 
Control and Prevention, the test-based criteria for discontinua-
tion of transmission-based precautions is the resolution of fever 
without the use of antipyretic drugs, improvement of respiratory 
symptoms, and negative results for SARS-CoV-2 RNA from at 
least two consecutive respiratory samples collected ≥24 hours 
apart [18]. Thus, two consecutive negative results from respira-
tory samples and clinical judgement are the minimum require-
ments for quarantine release.
CONCLUSION
Several EUA real-time RT-PCR assays for SARS-CoV-2 have en-
abled rapid diagnosis of COVID-19 with subsequent improve-
ment in infection control. However, proper testing and interpre-
tation of results require understanding the strengths and limita-
tions of EUA assays. Results of molecular diagnostic testing for 
COVID-19 should be interpreted in the context of the individual 
case presentation, clinical illness, and epidemiological correla-
tions.
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